Overview

• US biotechnology firm's Q4 net income turned positive, driven by higher collaboration and license revenue

• Operating expenses for Q4 increased year-over-year due to expanded R&D and clinical activities

• Company extended cash runway through end of 2027

Outlook

• Xilio expects to submit an IND for XTX501 in mid-2026 and start Phase 1 in H2 2026

• Company anticipates nominating a masked T cell engager candidate targeting PSMA and STEAP1 in Q2 2026

• Xilio expects its cash and equivalents to fund operations through end of 2027

Result Drivers

• COLLABORATION REVENUE - Co said higher collaboration and license revenue was mainly due to agreements and milestone payments with AbbVie and Gilead

• R&D EXPANSION - Co attributed higher R&D expenses to manufacturing for IND-enabling studies, preclinical development for XTX501, clinical activities for efarindodekin alfa, and masked T cell engager programs

• WARRANT EXERCISES & MILESTONE PAYMENTS - Co said cash position improved due to warrant exercises and milestone payments under collaborations

Company press release: ID:nGNXbKpj0f

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "strong buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Xilio Therapeutics Inc is $28.00, about 256.2% above its March 20 closing price of $7.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)